Ezetimibe

Expert Opinion on Investigational Drugs

Volumn 11, Issue 11, 2002, Pages 1587-1604

  Bays, Harold ^a  

^a Louisville Metabolic and Atherosclerotic Research Center   (United States)

Author keywords

ABCA1; ABCG5; ABCG8; ATP binding cassette transporter; CETP; Cholesterol; Cholesterol absorption inhibitor; Cholesterol synthesis; Cholesteryl ester transferase protein; Endogenous cholesterol; Exogenous cholesterol; Ezetimibe; Liver transaminase; Liver X receptors; Microsomal triglyceride transfer protein; MTP; Phytostanol; Phytosterol; SREBP 1; Sterol regulatory element binding protein

Indexed keywords

ANTACID AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; BILE ACID; CAMPESTEROL; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CIMETIDINE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYTOCHROME P450; DIGOXIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; SITOSTEROL; STANOL ESTER; SULFONYLUREA; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; WARFARIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FOOD COMPOSITION; HEREDITY; HUMAN; INTESTINE ABSORPTION; LIPID ABSORPTION; LIVER TOXICITY; MEDICAL RESEARCH; MONOTHERAPY; MYOPATHY; NONHUMAN; RAT; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 0036847994     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.11.1587     Document Type: Review

References (103)

1. CASTELLI WP: Epidemiology of coronary heart disease: the Framingham study. Am. J. Med. (1984) 76:4-12.
2. KANNEL WB, CASTELLI WP, GORDON T, MCNAMARA PM: Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann. Intern. Med. (1971) 74:1-12.
3. VERSCHUREN WMM, JACOBS DR, BLOEMBERG BPM et al.: Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five-year follow-up of the Seven Countries Study. JAMA (1995) 274:131-136.
4. STAMLER J, WENTWORTH D, NEATON JD: For the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA (1986) 256:2823-2828.
5. SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333:1301-1307.
6. DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA (1998) 279:1615-1622.
7. LIPID RESEARCH CLINICS PROGRAM: The Lipid Research Clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA (1984) 251:351-364.
8. FRICK MH, ELO O, HAAPA K et al.: 1987 Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med. (1987) 317:1237-1245.
9. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival study (4S). Lancet (1995) 345:1274-1275.
10. SACKS FM, MOYÉ LA, DAVIS BR et al.: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (1998) 97:1446-1452.
11. LIPID STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. (1998) 339:1349-1357.
12. HEART PROTECTIVE STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protective Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial. Lancet (2002) 360:7M-22M.
13. CORONARY DRUG PROJECT RESEARCH GROUP: Clofibrate and niacin in coronary heart disease. JAMA (1975) 231:360-381.
14. THE CORONARY DRUG PROJECT RESEARCH GROUP: Influence of adherence to treatment and response to cholesterol on mortality in the Coronary Drug Project. N. Engl. J. Med. (1980) 303:1038-1041.
15. HOERGER TJ, BALA MV, BRAY JW et al.: Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment eligible United States adults. Am. J. Cardiol. (1998) 82:61-65.
16. PEARSON TA, LAURORA I, CHU H, KAFONEK S: A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. (2000) 160:459-467.
17. BAYS HE, MOORE PB, DREHOBL MA et al.: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin. Ther. (2001) 23(8):1209-1230.
18. HALLIKAINEN MA, SARKKINEN ES, UUSITUPA MIJ: Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J. Nutr. (2000) 130:767-776.
19. PLAT J, MENSINK RP: Effect of plant stanol esters on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase mRNA expression in mononuclear blood cells of healthy men and women. FASEB J. (2002) 16(2):258-260.
20. VANHANEN H, KESANIEMI YA, MIETTINEN TA: Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal sterols, and cholesterol absorption in man. Metabolism (1992) 41:588-595.
21. GRUNDY SM, AHRENS EH Jr, SALEN G et al.: Mechanism of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J. Lipid Res. (1972) 13:531-551.
22. EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NCEP: Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA (2001) 285(19):2486-2497.
23. STEIN E, STRUTT KL, MILLER E et al.: ZD4522 is superior to atorvastatin in the treatment of patien ts with heterozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. (2001) 37(Suppl. 1):292A.
24. SHEPHERD J: The role of the exogenous pathway in hypercholesterolemia. Eur. Heart J. (2001) 3(Suppl. E):E2-E5.
25. COOPER AD: Role of the enterohepatic circulation of bile salts in lipoprotein metabolism. Gastroenterol. Clin. North Am. (1999) 28(1):211-229.
26. MAMO JCL, SMITH D, YU KCW et al.: Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolaemia. Eur. J. Clin. Invest. (1998) 28:379-384.
27. BAYS HE: Existing and investigational combination drug therapy for high density lipoprotein cholesterol. Am. J. Cardiol. (2002) (Suppl.):(In Press).
28. th Edn.). Murray RK, Granner DK, Mayes PA, Rodwell VW, Appleton & Lange, Stamford, Connecticut, USA (2000):285-305.
29. DIETSCHY JM, TURLEY SD, SPADY DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. (1993) 34(10):1637-1659.
30. CHANG CK, SNOOK JT. The cholesterolaemic effects of dietary fats in cholesteryl ester transfer protein transgenic mice. Br. J. Nutr. (2001) 85(6):643-648.
31. JANSEN S, LOPEZ-MIRANDA J, CASTRO P et al.: Low-fat and high monosaturated fatty acid diets decrease plasma cholesterol ester transfer protein concentrations in young, healthy normolipemic men. Am. J. Clin. Nutr. (2000) 72(1):36-41.
32. GYLLING H, KONTULA K, KOIVISTO UM, MIETTINEN HE, MIETTINEN TA: Polymorphism of the genes encoding apoproteins A-1, B, C-III, and E and LDL receptor, and cholesterol and LDL metabolism during increased cholesterol intake. Common alleles of the apoprotein E gene show the greatest regulatory impact. Arterioscler. Thromb. Vasc. Biol. (1997) 17(1):38-44.
33. STEINMETZ A. Intestinal apolipoprotein metabolism. Klin. Wochenschr. (1990) 68(Suppl. 22):12-18.
34. CATAPANO AL: Ezetimibe: A selective inhibitor of cholesterol absorption. Eur. Heart J. (2001) 3(Suppl. E):E6-E10.
35. SCHULTHESS G, COMPASSI S, BOFFELLI D et al: A comparative study of sterol absorption in different small-intestinal brush border membrane models. J. Lipid Res. (1996) 37:2405-2419.
36. HAUSER H, DYER JH, NANCY A et al.: Identification of a receptor mediating absorption of dietary cholesterol in the intestine. Biochemistry (1998) 37:17842-17850.
37. SCHULTHESS G, COMPASSI S, WERDER M et al.: Intestinal sterol absorption mediated by scavenger receptors is competitively inhibited by amphipathic peptides and proteins. Biochemistry (2000) 39:12623-12631.
38. LEE MH, LU K, HAZARD S et al.: Identification of a gene, ABCG5, important in the regulation of dietary cholesterol. Nat. Genet. (2001) 27(1):79-83.
39. VON BERGMANN K, SALEN G, LUTJOHANN D, MUSLINER T, MUSSER B: Ezetimibe effectively reduces serum plant sterols in patients with sitosterolemia. Atherosclerosis Suppl. 2002 3(2):232
40. REPA JJ, DIETSCHY JM, TURLEY SD: Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in either the intestinal bile acid pool or the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte. J. Lipid Res. (2002):(In Press).
41. DUJOVNE C, HELD J, LIPKA L et al.: Does cholesterol and/or fat intake affect plasma lipid efficacy of ezetimibe? J. Am. Coll. Cardiol. (2002) 39(5, Suppl. A):227A.
42. VAN HEEK M, FARLEY C, COMPTON DS et al.: Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol. (2000) 129:1748-1754.
43. VAN HEEK M, FARLEY C, COMPTON D et al.: The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically. Atherosclerosis (2000) 151:155. (Abstract).
44. KOSOGLOU T, KAKKAR T, STATKEVICH P et al.: Multiple-dose safety and pharmacokinetics of ezetimibe in adolescent children. Clin. Pharmacol. Ther. (2001) 69(2):P52.
45. STEIN E: Results of Phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur. Heart. J. (2001) 3(Suppl. E):E11-E16.
46. ZHU Y, STATKEVICH P, KOSOGLOU T et al., Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. Clin. Pharmacol. Ther. (2000) 67:152 (Abstract).
47. KNOPP RH, BAYS H, MANION CV et al.: Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. Atherosclerosis (2001) 2(Suppl. 2):90.
48. COURTNEY RD, KOSOGLOU T, STATKEVICH P et al.: Effect of antacid on the pharmacokinetics of ezetimibe. Clin. Pharmacol. Ther. (2002) 71:P80.
49. BAUER KS, KOSOGLOU T, STATKEVICH P et al.: Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin. Clin. Pharmacol. Ther. (2001) 69: (Abstract P5).
50. KEUNG ACF, KOSOGLOU T, STATKEVICH P et al.: Ezetimibe does not affect the pharmacokinetics of oral contraceptives. Clin. Pharmacol. Ther. (2001) 69:Abstract P55.
51. KOSOGLOU T, GUILLAUME M, SUN S et al.: Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe [abstract]. Atherosclerosis (2001) 2(Suppl. 2):38.
52. KOSOGLOU T, STATKEVICH P, BAUER KS et al.: Ezetimibe does not alter the pharmacokinetics and pharmacodynamics of digoxin [abstract]. AAPS Pharm Sci. 2001 AAPS Annual Meeting Suppl. (2001): (Abstract 3).
53. STATKEVICH P, REYDERMAN L, KOSOGLOU T et al.: Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide. Clin. Pharmacol. Ther. (2001) 69:(Abstract P67).
54. KOSOGLOU T, MEYER I, MUSIOL B et al.: Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications. Atherosclerosis (2001) 2(Suppl.):89(Abstract).
55. STATKEVICH P, ZHU Y, KOSOGLU T et al.: SCH 58235 does not affect the pharmacokinetics of simvastatin. Clin. Pharmacol. Ther. (200) 67(2):146.
56. ZHU Y, STATKEVICH P, KOSOGLOU T et al.: Lack of a pharmacokinetic interaction between ezetimibe and atorvastatin. Clin. Pharmacol. Ther. (2001) 69(2):P68.
57. REYDERMAN L, KOSOGLOU T, STATKEVICH P et al.: No pharmacokinetic drug interaction between ezetimibe and lovastatin. Clin. Pharmacol. Ther. (2001) 69(2):P66.
58. KOSOGLOU T, EIBERLING M, STATKEVICH P et al.: Pharmacodynamic interaction between cerivastatin and the selective cholesterol absorption inhibitor ezetimibe. Eur. Heart J. (2001) 22(Suppl. 252): (Abstract).
59. MIETTINEN TA, GYLLING H: Regulation of cholesterol metabolism by dietary plant sterols. Curr. Opin. Lipidol. (1999) 10:9-14.
60. MIETTINEN TA: Cholesterol absorption inhibition: A stradegy for cholesterol lowering therapy. Int. J. Clin. Pract. (2001) 55(10):710-716.
61. RAEINI-SARJAZ M, NTANIOS FY, VANSTONE CA, JONES PJ: No changes in serum fat-soluble vitamin and carotenoid concentrations with the intake of plant sterol/stanol esters in the context of a controlled diet. Metabolism (2002) 51(5):652-656.
62. TAMMI A, RONNEMAA T, GYLLING H et. al.: Plant stanol ester margarine lowers serum total and low-density lipoprotein cholesterol concentration of healthy children: The STRIP project. J. Pediatr. (2000) 136(4):503-510.
63. VAN HEEK M, FARLEY C, COMPTON D, HOOS L, DAVIS H. The novel cholesterol absorption inhibitor, ezetimibe, selectively inhibits the intestinal absorption of free cholesterol in the presence and absence of exocrine pancreatic function. Atherosclerosis (2000) 151:155. (Abstract).
64. COURTNEY RD, KOSOGLOU T, STATKEVICH et al.: Effect of food on the oral bioavailability of ezetimibe. Clin. Pharmacol. Ther. (2002) 71(2):P80.
65. VAN HEEK M, COMPTON DS, DAVIS HR: The cholesterol absorption inhibitor ezetimibe decreases diet-induced hypercholesterolemia in monkeys. Eur. J. Pharmacol. (2001) 415:79-84.
66. DAVIS HR, COMPTON DS, HOOS L, TETZLOFF G: The cholesterol inhibitor ezetimibe inhibits the development of atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets. Atherosclerosis (2000) 151:133 (Abstract).
67. DAVIS HR JR, PULA KK, ALTON KB, BURRIER RE, WATKINS RW. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor ezetimibe in combination with 3-hydroxy-3-methylgultaryl coenzyme a reductase inhibitors in dogs. Metabolism (2001) 50(10):1234-1241.
68. KNOPP RH, GITTER H, TRUITT T et al.: Ezetimibe reduces low-density lipoprotein cholesterol: results of a Phase III, randomized, double-blind, placebo-controlled trial. Atherosclerosis (2001) 2(Suppl. 2):38.
69. BAYS HE, KNOPP RH, MANION CV et al.: Ezetimibe does not decrease the response to cosyntropin stimulation. Atherosclerosis (2001) 2(Suppl. 2):95 (Abstract P193).
70. DUJOVNE CA, ETTINGER MP, MCNEER JF et al.: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol. (2002):(In Press).
71. BAYS HE, WEISS S, GAGNE C et al.: Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia. Oral Contributions. J. Am. Coll. Cardiol. (2002) 39(5, Suppl. A): 833-834.
72. GAGNE C, BAYS HE, WEISS SR et al.: For the Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. (2002):(In Press).
73. ADULT TREATMENT PANEL II: Summary of the Second Report of the National Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA (1993) 269:3015-3023.
74. DAVIDSON MH, MCGARRY T, BETTIS R et al.: Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 39(5, Suppl. A):226A.
75. BALLANTYNE C, HOURI J, NOTARBARTOLO A et al: Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 39(5, Suppl. A):227A.
76. LIPKA L, KERZNER B, CORBELLI J et al.: Ezetimibe coadministered with lovastatin in patients with primary hypercholesterolemia. Abstract Presentation. J. Am. Col. Cardiol. (2002) 39(Suppl. B):430B.
77. MELANI L, MILLS R, HASSMAN D et al.: Ezetimibe coadministered with pravastatin in 538 patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 39(Suppl. B):139B.
78. LEWIS JH: Drug-induced liver disease. Med. Clin. North Am. (2000) 84(5):1275-1311.
79. DAVIDSON MH: Rosuvastastin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin. Investig. Drugs (2002) 11(1):125-141.
80. OLSSON AG, PEARS J, MCKELLAR J et al.: Effect of rosuvastatin on low-density cholesterol in patients with hypercholesterolemia. Am. J. Cardiol. (2001) 88(5):504-508.
81. BROWN VW, BAYS HE, HASSMAN HA et al.: Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am. Heart J. (2002):(In Press).
82. LEITERSDORF E: Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management. Eur. Heart J. (2001) 3(Suppl. E):El7-E23.
83. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
84. HEUER T, GERARDS H, PAUW M et al.: Toxic liver damage caused by HMG-CoA reductase inhibitors. Med. Klin. (2000) 95(11):642-644.
85. DUJOVNE CA: Side effect of statins: hepatitis versus 'transaminitis' - myositis versus 'CPKitis'. Am. J. Cardiol. (2002) 89(12):1411-1413.
86. DAVISDSON MH, DILLON MA, GORDON B et al.:Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med (1999) 159:1893-1900.
87. RILEY TR, BHATTI AM: Preventive strategies in chronic liver disease: part 1. Alcohol, vaccines, toxic medications and supplements, diet and exercise. Am. Fam. Physician (2001) 64(9):1555-1560.
88. BAZALO GR. Managed care trends in statin usage. Manag. Care (2001) 10:48-59.
89. GAGNÉ C, GAUDET D, BRUCKERT E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation (2002) 105:2469.
90. KOSOGLOU T, GUILLAUME M, SUN S et al.: Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe. Atherosclerosis (2001) 2(Suppl. 2):38.
91. OSBORNE TF: Sterol regulatory element-binding proteins (SREBP): key regulators of nutritional homeostasis and insulin action. J. Biol. Chem. (2000) 275(42):32379-32382.
92. SCHULTZ JR, TU H, LUK A et al.: Role of LXRs in control of lipogenesis. Genes Dev. (2000) 14(22):2831-2838.
93. EDWARDS PA, KAST HR, ANISFELD AM: BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. (2002) 43(1):2-12.
94. REPA JJ, BERGE KE, POMAJZL C, RICHARDSON JA, HOBBS H, MANGELSDORF DJ: Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. (2002) 277(21):18793-18800.
95. OSTLUND RE: Cholesterol absorption. Curr. Opin. Gastroenterol. (2002) 18:254-258.
96. REPA JJ, TURLEY SD, LOBACCORO JA et al.: Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 289:1524.
97. ALTMANN SW, DAVIS HR, YAO X et al.: The identification of Scavenger Receptor Class B, Type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochim. Biophys. Acta (2002) 1580:77-93.
98. GYLLING H, MIETTINEN TA: Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypoplipidaemic treatments in coronary patients. Atherosclerosis (Ireland) (2002) 160(2):477-481.
99. THOMPSON GR, O'NEILL F, SEED M: Why some patients respond poorly to statins and how this might be remedied. Eur. Heart J. (2002) 23(3):200-206.
100. SIMONEN P, GYLLING H, MIETTINEN TA: body weight modulates cholesterol metabolism in non-insulin dependent type 2 diabetics. Obes. Res. (2002) 10:328-335.
101. SIMONEN P, GYLLING H, HOWARD AN, MIETTINEN TA: Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am. J. Clin. Nutr. (2000) 72(1):82-88.
102. JIANG Y, NOH SK, KOO SI: Egg phosphatidylcholine decreases the lymphatic absorption of cholesterol in rats. J. Nutr. (2001) 131(9):2358-2363.
103. BERGE KE, TIAN H, GRAF GA et al.: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 5497:1771-1775.